Drug
Mirabegron clinical trials
Also written YM178, Myrbetriq and Betmiga.
- studies test it
- 141
- open now
- 22
- in phase 3
- 30
- first study started
- 2003
Keep track of what changes. Save the mirabegron studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
140 studies that test it; most in 2016 (12)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 11 |
| 2009 | 9 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 6 |
| 2014 | 11 |
| 2015 | 11 |
| 2016 | 12 |
| 2017 | 7 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 9 |
| 2022 | 10 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 4 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 36
- Phase 2
- 31
- Phase 3
- 30
- Phase 4
- 38
- No phase
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 58 · Other 83
Astellas Pharma Inc (32) · Astellas Pharma Europe B.V. (13) · Astellas Pharma Global Development, Inc. (5) · Far Eastern Memorial Hospital (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Cedars-Sinai Medical Center (3) · Astellas Pharma China, Inc. (3) · Philip Kern (3)
Often tested with
Tested in the same studies.
Solifenacin (19) · Tamsulosin (7) · Tolterodine (6) · Tadalafil (3) · Digoxin (2) · Cholinergic Antagonists (2) · Estrogens (2) · Montelukast (1)
Studies
Open first, then newest update. How each study uses mirabegron is read from its arms, and is right about nine times in ten.
Testing it · 141
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With ObesityNot yet recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT05713799Written as Mirabegron
- Efficacy and Safety of Mirabegron in Intracerebral HemorrhageRecruitingPhase 2Tianjin Medical University General HospitalNCT05369351Written as Standard treatment+mirabegron
- Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson DiseaseNot yet recruitingPhase 4VA Office of Research and DevelopmentNCT07187466Written as mirabegron
- Comparison of Mirabegron and Tamsulosin for Ureteral Stone ExpulsionRecruitingPhase 4Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationNCT07310797Written as Mirabegron
- Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPHRecruitingPhase 4University of California, San FranciscoNCT07829029Written as Mirabegron
- The Effects of Mirabegron and Tadalafil on Glucose Tolerance in PrediabeticsRecruitingPhase 4Philip KernNCT05051436Written as Mirabegron 50 MG
- Mechanisms for Activation of Beige Adipose Tissue in HumansRecruitingPhase 2Philip KernNCT04666636Written as Mirabegron
- Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)RecruitingPhase 3University of AarhusNCT06551246Written as Mirabegron
- Beta-3 Enhanced Autonomic Therapy for POTSNot yet recruitingPhase 2Cedars-Sinai Medical CenterNCT07585513Written as Mirabegron
- Using Mirabegron to Control Arrhythmia-1Not yet recruitingPhase 2Cedars-Sinai Medical CenterNCT07566208Written as Mirabegron
- TReating Incontinence for Underlying Mental and Physical HealthRecruitingPhase 4University of California, San FranciscoNCT05362292Written as Mirabegron
- Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNERecruitingPhase 3Mansoura UniversityNCT07199894Written as Mirabegron (beta3-adrenoceptor agonist), Anticholinergics
- Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related SymptomsRecruitingPhase 3Bir HospitalNCT06803030Written as Mirabegron 25 mg
- The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled TrialNot yet recruitingPhase 3Far Eastern Memorial HospitalNCT07114640Written as Mirabegron 25mg
- Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive BladderRecruitingPhase 4Mackay Memorial HospitalNCT06479720Written as Mirabegron with vaginal estrogen cream
- Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian CancerRecruitingPhase 2/3Obstetrics & Gynecology Hospital of Fudan UniversityNCT06791460Written as Pegylated liposomal doxorubicin plus adebrelimab with mirabegron
- Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder SyndromeRecruitingPhase 4Walter Reed National Military Medical CenterNCT05221021Written as Mirabegron 50 MG [Myrbetriq]
- Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyRecruitingPhase 2Zhejiang Provincial People's HospitalNCT06534762Written as Mirabegron
- A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)Not yet recruitingPhase 2Seoul National University HospitalNCT06181591Written as Mirabegron 50 MG
- Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus SolifenacinRecruitingPhase 3Far Eastern Memorial HospitalNCT04023253Written as Mirabegron
See all 141 studies that test mirabegron →
Given in every arm · 6 — mirabegron is usual care beside what is tested
- Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older WomenActive, not recruitingPhase 4Shachi TyagiNCT05604222Written as Mirabegron 50 MG
- Behavioral Interventions Versus Pelvic Floor Muscle Therapy as Adjuncts to Anticholinergic Pharmacotherapy for Urgency Urinary Incontinence: A Non-Inferiority TrialActive, not recruitingNot applicableEmilio José Dávila ÁlvarezNCT07259148Written as Oxybutynin / Mirabegron (Standardized Pharmacotherapy)
- Activation of Brown Adipose Tissue Metabolism Using MirabegronCompletedNot applicableUniversité de SherbrookeNCT04823442Written as Mirabegron
- Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.CompletedPhase 4Astellas Pharma IncNCT02294396Written as Mirabegron tablet
- Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive BladderCompletedNot applicableSerdinsek TamaraNCT06123364Written as mirabegron 50 mg daily
- To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of MetoprololCompletedPhase 1Astellas Pharma IncNCT01478490Written as mirabegron
As the comparator · 6 — what is tested is compared with mirabegron
- Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled StudyNot yet recruitingPhase 4Universidade do PortoNCT07711808Written as Mirabegron
- Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of FallsCompletedEarly Phase 1The University of Texas Medical Branch, GalvestonNCT05880862Written as Mirabegron
- Study of ONO-8577 in Patients With Overactive BladderCompletedPhase 2Ono Pharmaceutical Co. LtdNCT03106623Written as solifenacin succinate + mirabegron
- Acupuncture Combined With Mirabegron in the Treatment of OABActive, not recruitingPhase 1The Affiliated Ganzhou Hospital of Nanchang UniversityNCT06181019Written as 50 mg of mirabegron
- Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)CompletedPhase 1Genuine Research Center, EgyptNCT05767632Written as Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)
- Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive BladderWithdrawnNot applicableUniversity Hospitals Cleveland Medical CenterNCT03087578Written as Mirabegron 50 MG [Myrbetriq]
Codes
What other systems call mirabegron · ClinicalTrials.gg INT005090
- MeSH (NLM) C520025mirabegronConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) MVR3JL3B2VMIRABEGRONConfirmed FDA, NLM, Wikidata
- RxNorm 1300786Confirmed FDA, Wikidata
- Wikidata Q3702534mirabegronConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90633MirabegronOne source FDA
- DrugBank DB08893One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C520025 | mirabegron | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | MVR3JL3B2V | MIRABEGRON | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1300786 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3702534 | mirabegron | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90633 | Mirabegron | One source FDA |
| DrugBank | DB08893 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.